Unity Biotech 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
foselutoclax (UBX1325) / Unity Biotech
ENVISION, NCT05275205: Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration

Completed
2
51
US
UBX1325 injection 50 μL, EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Unity Biotechnology, Inc.
Neovascular Age-related Macular Degeneration
02/23
07/23
BEHOLD, NCT04857996: Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema

Completed
2
65
Canada, US
UBX1325, Sham
Unity Biotechnology, Inc.
Diabetic Macular Edema (DME)
04/23
04/23
ASPIRE, NCT06011798: Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME

Completed
2
52
US
Aflibercept, foselutoclax, UBX1325
Unity Biotechnology, Inc.
Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
01/25
04/25
UBX-1967 / Ascentage Pharma
No trials found
UBX2050 / Unity Biotech
No trials found
UBB2048 / Unity Biotech
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
foselutoclax (UBX1325) / Unity Biotech
ENVISION, NCT05275205: Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration

Completed
2
51
US
UBX1325 injection 50 μL, EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Unity Biotechnology, Inc.
Neovascular Age-related Macular Degeneration
02/23
07/23
BEHOLD, NCT04857996: Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema

Completed
2
65
Canada, US
UBX1325, Sham
Unity Biotechnology, Inc.
Diabetic Macular Edema (DME)
04/23
04/23
ASPIRE, NCT06011798: Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME

Completed
2
52
US
Aflibercept, foselutoclax, UBX1325
Unity Biotechnology, Inc.
Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
01/25
04/25
UBX-1967 / Ascentage Pharma
No trials found
UBX2050 / Unity Biotech
No trials found
UBB2048 / Unity Biotech
No trials found

Download Options